CA2287538A1 - Formes tronquees de proteines apparentees au facteur vegf - Google Patents
Formes tronquees de proteines apparentees au facteur vegf Download PDFInfo
- Publication number
- CA2287538A1 CA2287538A1 CA002287538A CA2287538A CA2287538A1 CA 2287538 A1 CA2287538 A1 CA 2287538A1 CA 002287538 A CA002287538 A CA 002287538A CA 2287538 A CA2287538 A CA 2287538A CA 2287538 A1 CA2287538 A1 CA 2287538A1
- Authority
- CA
- Canada
- Prior art keywords
- vrp
- truncated
- subunit
- sequence
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Cette invention se rapporte à de nouvelles formes tronquées de protéines apparentées au facteur de croissance endothéliale vasculaire (VRP) qui servent à stimuler l'engiogenèse in vitro et in vivo. Cette invention se rapporte également à des acides nucléiques codant ces nouvelles protéines VRP tronquées et à des procédés pour produire ces protéines VRP tronquées. Des compositions pharmaceutiques contenant ces protéines VRP tronquées et des procédés de thérapie génétique utilisant les acides nucléiques qui codent ces protéines VRP tronquées peuvent servir dans le traitement des maladies cardiaques et pour la cicatrisation des plaies.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84298497A | 1997-04-25 | 1997-04-25 | |
US08/842,984 | 1997-04-25 | ||
PCT/US1998/007801 WO1998049300A2 (fr) | 1997-04-25 | 1998-04-20 | Formes tronquees de proteines apparentees au facteur vegf |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2287538A1 true CA2287538A1 (fr) | 1998-11-05 |
Family
ID=25288752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002287538A Abandoned CA2287538A1 (fr) | 1997-04-25 | 1998-04-20 | Formes tronquees de proteines apparentees au facteur vegf |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0977854A2 (fr) |
JP (1) | JP2001524828A (fr) |
KR (1) | KR20010020259A (fr) |
CN (2) | CN1260835A (fr) |
AU (1) | AU7250298A (fr) |
CA (1) | CA2287538A1 (fr) |
EA (1) | EA199900861A1 (fr) |
IL (1) | IL132537A0 (fr) |
NZ (2) | NZ514872A (fr) |
WO (1) | WO1998049300A2 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
EP0751992B1 (fr) | 1994-03-08 | 2005-11-09 | Human Genome Sciences, Inc. | Facteur 2 de croissance endotheliale vasculaire |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
DK0848755T4 (da) | 1995-09-08 | 2011-05-23 | Genentech Inc | VEGF relateret protein |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
AU3072099A (en) * | 1998-03-13 | 1999-09-27 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
AU3203299A (en) * | 1998-03-27 | 1999-10-18 | Dorothea J. Eicher | Vegf and vegf-c as infant formula supplements |
DE19813774A1 (de) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) |
DE69928411D1 (de) | 1998-09-08 | 2005-12-22 | Agouron Pharma | Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung |
EP1568375A1 (fr) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Utilisation des protéines VEGF-C ou VEGF-D pour la prévention de la resténose |
PT1126870E (pt) * | 1998-10-26 | 2005-01-31 | Licentia Ltd | Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
WO2000024415A2 (fr) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
WO2001057181A2 (fr) * | 2000-02-04 | 2001-08-09 | Carmeliet, Peter | UTILISATION DU FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE, DU FACTEUR DE CROISSANCE DU PLACENTA OU DES DEUX FACTEURS DANS LA PREVENTION OU LE TRAITEMENT DE MALADIES ISCHEMIQUES OU D'ACCIDENTS CEREBROVASCULAIRES |
WO2001077328A1 (fr) | 2000-04-06 | 2001-10-18 | Franco Wayne P | Methodes d'utilisation de facteurs de croissance pour traiter une cardiopathie |
EP1157999A1 (fr) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci |
WO2002011769A1 (fr) | 2000-08-04 | 2002-02-14 | Human Genome Sciences, Inc. | Facteur 2 de croissance endothéliale (vegf-2) |
EP1323736A4 (fr) * | 2000-08-10 | 2005-08-24 | Masabumi Shibuya | Facteur de croissance chimere de cellules endotheliales vasculaires de type humain |
EP1191104A1 (fr) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Vehicules de trasport génique et leur utilisation dans preparations medicaux et de vaccines |
AU2884102A (en) | 2000-12-07 | 2002-06-18 | Sangamo Biosciences Inc | Regulation of angiogenesis with zinc finger proteins |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
EP1385864B1 (fr) | 2001-04-13 | 2010-06-09 | Human Genome Sciences, Inc. | Anticorps anti-VEGF-2 |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
JP2005505510A (ja) * | 2001-06-20 | 2005-02-24 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Vegf−bによる血管新生の刺激 |
JP4418676B2 (ja) | 2001-10-15 | 2010-02-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 虚血性損傷を減らすための置換された4−フェニル−4−(1h−イミダゾール−2−イル)−ピペリジン誘導体 |
WO2006055743A2 (fr) * | 2004-11-18 | 2006-05-26 | Franco, Wayne | Combinaison de therapie au facteur de croissance et de therapie cellulaire pour le traitement de maladies aigues et chroniques des organes |
WO2010078624A1 (fr) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Matériaux et méthodes pour le traitement de l’hypertension |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
WO1994011506A1 (fr) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Transfert de genes au moyen d'un adenovirus au muscle lisse cardiaque et vasculaire |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6100242A (en) * | 1995-02-28 | 2000-08-08 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
ES2206558T3 (es) * | 1995-03-02 | 2004-05-16 | Amrad Operations Pty.,Ltd. | Nuevo factor de crecimiento y secuencia genetica que lo codifica. |
EP0873348A4 (fr) * | 1995-06-06 | 2000-11-08 | Human Genome Sciences Inc | Facteur de croissance 3 de l'endothelium vasculaire humain |
-
1998
- 1998-04-20 CN CN98806232A patent/CN1260835A/zh active Pending
- 1998-04-20 IL IL13253798A patent/IL132537A0/xx unknown
- 1998-04-20 WO PCT/US1998/007801 patent/WO1998049300A2/fr not_active Application Discontinuation
- 1998-04-20 NZ NZ514872A patent/NZ514872A/en unknown
- 1998-04-20 CN CNA200510009104XA patent/CN1680442A/zh active Pending
- 1998-04-20 CA CA002287538A patent/CA2287538A1/fr not_active Abandoned
- 1998-04-20 KR KR1019997009857A patent/KR20010020259A/ko not_active Application Discontinuation
- 1998-04-20 AU AU72502/98A patent/AU7250298A/en not_active Abandoned
- 1998-04-20 NZ NZ500530A patent/NZ500530A/en unknown
- 1998-04-20 EP EP98919794A patent/EP0977854A2/fr not_active Withdrawn
- 1998-04-20 EA EA199900861A patent/EA199900861A1/ru unknown
- 1998-04-20 JP JP54706298A patent/JP2001524828A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
IL132537A0 (en) | 2001-03-19 |
CN1260835A (zh) | 2000-07-19 |
WO1998049300A3 (fr) | 1999-03-11 |
NZ500530A (en) | 2001-12-21 |
JP2001524828A (ja) | 2001-12-04 |
EA199900861A1 (ru) | 2000-06-26 |
EP0977854A2 (fr) | 2000-02-09 |
WO1998049300A2 (fr) | 1998-11-05 |
AU7250298A (en) | 1998-11-24 |
KR20010020259A (ko) | 2001-03-15 |
CN1680442A (zh) | 2005-10-12 |
NZ514872A (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2287538A1 (fr) | Formes tronquees de proteines apparentees au facteur vegf | |
EP0925360B1 (fr) | Facteur angiogeniqueutilisation de facteur angiogenique vegf145 dans le traitement de maladies cardiovasculaires | |
US6479654B1 (en) | Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF | |
JP2000069982A (ja) | ヒト血管内皮増殖因子2 | |
CA2220912A1 (fr) | Facteur de croissance humain du type ccn | |
CA2322748A1 (fr) | Facteur de croissance endothelial vasculaire 2 | |
JP2002541829A (ja) | 遺伝子治療および治療的スクリーニングに有用なeNOS変異体 | |
US20030165467A1 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
EP1141293A2 (fr) | Facteur de croissance endotheliale vasculaire- x | |
EP0796325A1 (fr) | Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide | |
US20020034738A1 (en) | Human vascular ibp-like growth factor | |
US6287812B1 (en) | Nucleic acid molecules encoding cytostatin I | |
EP1426444A2 (fr) | Utilisation du facteur d'angiogénèse VEGF145 dans le traitement de maladies cardiovasculaires | |
US20060084622A1 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
Neufeld et al. | VEGF 145 expression vectors | |
AU8936101A (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
KR100407087B1 (ko) | 사람혈관성ibp-유사성장인자 | |
AU2004200697A1 (en) | Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF | |
CA2206640A1 (fr) | Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide | |
JP2002247983A (ja) | ヒト血管ibp様成長因子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |